Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease

Journal of the American Academy of Dermatology

Volumn 64, Issue 4, 2011, Pages 773-778

  Li, Yaohan ^a   Foshee, J B ^a   Sontheimer, Richard D ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

autoimmune blistering disease; bullous pemphigoid; epidermolysis bullosa acquisita; rituximab

Indexed keywords

CLOBETASOL; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS;

ADULT; ALOPECIA; ARTICLE; BLISTER; BULLOUS SKIN DISEASE; CASE REPORT; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; GRAM NEGATIVE SEPSIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUCOUS MEMBRANE PEMPHIGOID; PRIORITY JOURNAL; REMISSION; SCAR FORMATION; SKIN BIOPSY; SKIN ULCER;

EID: 79952815388     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.09.045     Document Type: Review

References (25)

1. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol 2001;66:142-4. (Pubitemid 32096630)
2. Schmidt E, Hunzelmann N, Zillikens D, Brocker EB, Goebeler M. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006;31:503-8. (Pubitemid 43806580)
3. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of auto-immune bullous skin diseases. J Dtsch Dermatol Ges 2008;6:366-73.
4. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR, Ahmed AR, Spigelman Z, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-9. (Pubitemid 44631360)
5. Woodley DT, Remington J, Chen M, Woodley DT, Remington J, Chen M. Autoimmunity to type VII collagen: epidermolysis bullosa acquisita. Clin Rev Allergy Immunol 2007;33:78-84.
6. Joly P, Mouquet H, Roujeau JC, D'Incan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007;357:545-52. (Pubitemid 47236279)
7. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P, et al. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol 2007;143:1033-8. (Pubitemid 47296080)
8. Schmidt E, Benoit S, Brocker EB, Zillikens D, Goebeler M, Schmidt E, et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol 2006;142:147-50. (Pubitemid 43276525)
9. Niedermeier A, Eming R, Pfutze M, Neumann CR, Happel C, Reich K, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 2007;143:192-8. (Pubitemid 46294584)
10. Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol 2007;156:194-6. (Pubitemid 44924179)
11. Taverna JA, Lerner A, Bhawan J, Demierre MF, Taverna JA, Lerner A, et al. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol 2007;6:731-2.
12. Daito J, Katoh N, Asai J, Ueda E, Takenaka H, Ishii N, et al. Brunsting-Perry cicatricial pemphigoid associated with autoantibodies to the C-terminal domain of BP180. Br J Dermatol 2008;159:984-6.
13. Joly P, Ruto F, Thomine E, Delpech A, Balguerie X, Tron F, et al. Brunsting-Perry cicatricial bullous pemphigoid: a clinical variant of localized acquired epidermolysis bullosa? J Am Acad Dermatol 1993;28:89-92.
14. Kurzhals G, Stolz W, Meurer M, Kunze J, Braun-Falco O, Krieg T. Acquired epidermolysis bullosa with the clinical feature of Brunsting-Perry cicatricial bullous pemphigoid. Arch Dermatol 1991;127:391-5.
15. Karpouzis A, Prost C, Cordoliani F, Viguier D, Blum L, Puissant A. Acquired localized epidermolysis bullosa: a case with scalp involvement and immunoelectron microscopic study [French]. Ann Dermatol Venereol 1993;120:464-8.
16. Osawa M, Demitsu T, Toda S, Yokokura H, Umemoto N, Yamada T, et al. A case of mixed bullous disease of epidermolysis bullosa acquisita and linear IgA bullous dermatosis. Dermatology 2005;211:146-8. (Pubitemid 41160251)
17. Kraigher O, Wohl Y, Gat A, Brenner S, Kraigher O, Wohl Y, et al. A mixed immunoblistering disorder exhibiting features of bullous pemphigoid and pemphigus foliaceus associated with Spirulina algae intake. Int J Dermatol 2008;47:61-3.
18. Sami N, Ahmed AR. Dual diagnosis of pemphigus and pemphigoid: retrospective review of thirty cases in the literature. Dermatology 2001;202:293-301. (Pubitemid 32664523)
19. Sami N, Bhol KC, Beutner EH, Plunkett RW, Leiferman KM, Foster CS, et al. Simultaneous presence of mucous membrane pemphigoid and pemphigus vulgaris: molecular characterization of both autoantibodies. Clin Immunol 2001;100:219-27.
20. Tchernev G, Orfanos CE. Antigen mimicry, epitope spreading and the pathogenesis of pemphigus. Tissue Antigens 2006;68:280-6. (Pubitemid 44536201)
21. Vanderlugt CL, Begolka WS, Neville KL, Katz-Levy Y, Howard LM, Eagar TN, et al. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol Rev 1998;164:63-72. (Pubitemid 28438396)
22. Deshmukh US, Bagavant H, Lewis J, Gaskin F, Fu SM, Deshmukh US, et al. Epitope spreading within lupus-associated ribonucleoprotein antigens. Clin Immunol 2005;117:112-20. (Pubitemid 41407720)
23. Dai YD, Carayanniotis G, Sercarz E, Dai YD, Carayanniotis G, Sercarz E. Antigen processing by autoreactive B cells promotes determinant spreading. Cell Mol Immunol 2005;2:169-75.
24. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008;128:2850-8.
25. Mouquet H, Musette P, Gougeon ML, Jacquot S, Lemercier B, Lim A, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008;128:2859-69.